🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being described as a "major milestone" in the fight against superbug strains of the infection, according to scientists.

A Global Challenge

Gonorrhoea infections are increasing worldwide, with estimates suggesting over 82 million instances each year. Especially elevated rates are seen in Africa and nations within the World Health Organization's Western Pacific region, which encompasses China and Mongolia to New Zealand. In England, cases have reached a all-time high, while figures across Europe in 2023 were triple the level compared to those in 2014.

“The authorization of novel therapies for gonorrhoea is an significant and necessary advancement in the face of rising global incidence, escalating drug resistance and the extremely scarce treatment choices at this time.”

Health officials are deeply concerned about the increase in drug-resistant strains. The World Health Organization has classified it as a "high-priority threat". Ongoing monitoring showed that resistance to key first-line drugs like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Two New Therapies Gain Authorization

One new antibiotic, marketed under the name Nuzolvence, was cleared by the US FDA in mid-December for treating gonorrhoea. This infection can lead to significant complications, including infertility. Experts anticipate that focused deployment of this new drug will help delay the emergence of superbugs.

Gepotidacin, developed by the drugmaker GSK, was also approved in the same week. This medication, which is also used to treat UTIs, was proven in research to be able to combat antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Approach to Creation

This new treatment was the result of a innovative non-profit model for drug creation. The charitable organization Global Antibiotic Research & Development Partnership partnered with the pharmaceutical company Innoviva to bring it to fruition.

“This authorization signifies a significant shift in the treatment of superbug gonorrhoea, which previously has been outpacing medical innovation.”

Testing Results and Global Access

As per data released by a prominent scientific publication, the new drug cured more than 90% of genital gonorrhoea infections. This places it at an equal footing with the current standard treatment, which combines two antibiotics. The study included over 900 participants from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its development partnership, GARDP has the rights to license and sell the drug in numerous low-income and middle-income countries.

Doctors on the front lines have expressed positive views. Having a easy-to-administer therapy of this kind is seen as a "critical tool" for public health efforts. This is deemed essential to alleviate the strain of the disease for individuals and to stop the proliferation of untreatable gonorrhoea worldwide.